Sheet 1

AUG 1 3 2007

PTO/SB/08A (04-07) Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 47

Complete if Known						
Application Number	09/904,356					
Filing Date	July 12, 2001					
First Named Inventor	G.P. Allaway et al.					
Art Unit	1968					
Examiner Name	Jeffery S. Parkin					
Attorney Docket Number	43966-CB					

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Boson Columns Lines M/horn	
Initials* No.1		Number-Kind Code ² (# known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevant Figures Appear	
\sim		US- 6,258,527	07-10-2001	Littman		
0		US- 6,258,782	07-10-2001	Barney et al.		
		US- 6,265,184	07-24-2001	Gary		
		US- 6,268,477	06-31-2002	Gary		
		^{US-} 6,448,375	09-10-2002	Samson		
		^{US-} 6,692,745	02-17-2004	Olson		
		^{US-} 6,692,938	02-17-2004	Samson		
		US- 6,797,811	09-28-2004	Gary		
		US- 6,972,126	12-06-2005	Allaway		
		US- 6,800,447	10-05-2004	Samson		
		^{US-} 5,939,320	08-17-1999	Littman		
		^{US-} 5,817,767	10-06-1998	Allaway		
		^{US-} 6,100,087	08-08-2000	J. Rossi et al.		
		^{US-} 7,175,988	02-13-2003	V. Roschke et al.		
		US- 6,528,625	03-04-2003	L. Wu		
		^{US-} 6,548,636	04-15-2003	T. Dragic		
		^{US-} 7,118,859	10-10-2006	V.M. Litwin et al.		
		^{US-} 7,138,119	11-21-2006	W.C Olson et al.		
₩ .		^{US-} 6,930,174	08-16-2005	M. Samson et al.		

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
		Country Code ³ "Number ⁴ "Kind Code ³ (# known)	MM-DD-YYYY	,	Or Relevant Figures Appear					
X		WO 97/37005	10-27-1997							
4		WO 97/28258	08-07-1997							
		WO 97/44462	11-27-1997							
		WO 01/64710	09-07-2001							
		WO 02/068608	09-06-2002			Г				
3		WO 02/083172	10-24-2002							

Examiner Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

Transission is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and substiting the completed application form to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to cotholete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway et al.

Serial No.: 09/904,356 Filed: July, 12, 2001

Exhibit A

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/904,356 Filing Date July 12, 2001 First Named Inventor G.P. Allaway et al. Art Unit 1968 Examiner Name Jeffery S. Parkin

Complete if Known

(Use as many sheets as necessary)

Substitute for form 1449/PTO

Sheet 2 Attorney Docket Number 43966-CB

		T		DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (F known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevan Figures Appear
		^{US-} 7,151,087 B2	12-19-2006	C. Combadiere et al.	
O_1		^{US-} 7,129,055	10-31-2006	D. Littman et al.	
		US- 7,060,273	06-13-2006	W.C. Olson et al.	
		^{US-} 7,122,185	10-17-2006	W.C. Olson et al.	
		^{US-} 6,908,734	06-21-2005	T. Dragic et at.	
		^{US-} 2002-0068813 A1	06-06-2002	T. Dragic et al.	
		US- 2004-0161739	08-19-2004	M. Samson et al.	
		US- 2004-0110127	06-10-2004	M. Samson et al.	
		^{US-} 2005-0154193	07-14-2005	V. Roschke	
		US- 2003-0166024	09-04-2003	C. Rosen et al	
		^{US-} 2002-0048786	04-25-2002	C. Rosen et al.	
		^{US-} 2002-0061834	05-23-2002	C. Rosen et al.	
		^{US-} 2003-0166870	12-23-2004	L. Wu et al.	
		us- 2003-0195348	10-16-2003	C.Combadiere	
		US- 2003-0003440	01-02-2003	L. Lopalco	
		US- 2003-0092632	05-15-2003	T. Dragic	
		^{US-} 2007-0026441 A1	02-01-2007	W.C. Olson et al.	
		^{US-} 2004-0062767	04-01-2004	W.C. Olson et al.	
4		^{US-} 2003-0139571 A1	07-24-2003	T. Dragic et al.	

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ			
	Country Code ³ "Number ⁴ "Kind Code ⁵ (# known)		MM-DD-YYYY	Or Relevant Figures Ap					
X		WO 02/22077	03-21-2002						
VI		WO 03/072766	09-04-2003			T			
		WO 07/014114	02-01-2007			Г			
		WO 97/47318 A	12-18-1997			Г			
		WO 98/18826	05-07-1998			Г			
J		WO 02/064612	08-22-2002						

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Initials for reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Initials conformation to applicant. Applicant unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CER 197 and 198. The information is considered to the serial number of the substitute to the serial number of the patent document. The series of information is required by 37 CER 197 and 198. The information is considered to the serial number of the serial number of the patent document. The series of the series

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1459.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

43966-CB

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/904,356 Filing Date July 12, 2001 INFORMATION DISCLOSURE First Named Inventor G.P. Allaway STATEMENT BY APPLICANT Art Unit 1648 (Use as many sheets as necessary) Examiner Name Jeffery S. Parkin

Sheet 3

of 47

Attorney Docket Number

			U. S. PATENT	DOCUMENTS	·
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Retevant Figures Appear
X		^{US-} 10/081,128	02-22-2002	W.C. Olson et al.	
\overline{Q}_{1}		^{US-} 09/212,793	12-16-1998	W.C. Olson et al.	
		^{US-} 08/663,616	06-14-1996	G.P. Allaway	
T		^{US-} 08/673,682	06-25-1998	G.P. Allaway	
		^{US-} 08/874,570	06-13-1997	G.P. Allaway	
		^{US-} 08/874,618	06-13-1997	G.P. Allaway	1
		^{US-} 09/118,415	07-17-1998	V.M. Litwing	
		^{US-} 60/358,886	02-22-2002	W.C. Olson et al.	
		^{US-} 60/017,157	05-20-1996	D. Littman et al.	
		^{US-} 60/266,738	02-06-2001	W.C. Olson et al.	
		^{US-} 60/282,380	04-06-2001	W.C. Olson et al.	
		^{US-} 60/019,715	06-14-1996	W.C. Olson et al.	
		^{US-} 60/019,941	06-14-1996	G.P. Allaway et al.	
		US- 60/112,532	12-16-1998	W.C. Olson et al.	
		US- 60/185,667	02-29-2000	T. Dragic et al.	
		^{US-} 60/205,839	05-19-2000	T. Dragic et al.	
		^{US-} 60/267,231	02-07-2001	T. Dragic et al.	
		^{US-} 60/272,203	02-18-2001	T. Oragic	
*		US- 60/018,508	05-28-1996	C. Combadiere et al.	

	FOREIGN PATENT DOCUMENTS								
	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
		Country Code ³ "Number ⁴ "Kind Code ³ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	₹			
X		WO 01/55439	08-02-2001						
70		WO 01/58915	08-16-2001						
		WO 01/58916	08-16-2001			Г			
		WO 97/22698	06-26-1997						
		WO 97/44055	11-27-1997	,		Π			
J		WO 97/032019	09-04-1997						

Examiner Date

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include gropy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language
Translation is attached.

Trainsation is statemed. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1:14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 47

Complete if Known						
Application Number	09/904,356					
Filing Date	July 12, 2001					
First Named Inventor	G.P. Allaway					
Art Unit	1648					
Examiner Name	Jeffery S. Parkin					
Attorney Docket Number	43966-CB					

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Document Number Number/Rind/Code ^{2 of known}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
0		^{US-} 7,16€ 545	01-09-2007	Y. U				
1		US- 2007-0048820 A1	03-01-2007	G.P. Allaway				
		US- 2007 @@31408 A1	02-08-2007	W.C. Olson				
$\neg \vdash$		US- 2007-0020280 A1	01-25-2007	W.C. Olson				
T		US- 2007-0025983 A1	02-01-2007	V.M. Litwin				
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-			<u> </u>			
		US-						
		US-			†			
		US-		7.0				
		US-						
		US-						
		US-	<u> </u>		<u> </u>			

			IGN PATENT DOCU	MENTS		
Examiner Initiats*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
04			MM-DD-YYYY		Or Relevant Figures Appear	1
X		EP 96870021.1	03-01-1996			
1		EP 0883687 81	10-27-2004			Г
		EP 96870 02.9	08-06-1996			Γ
		EP 1145724 A2	10-17-2001			Г
		EP 114608 A2	10-17-2001			Γ
T		EP 1146122 A2	10-17-2001			

	<u> </u>					
Examiner		Date		7		
Signature	2	Considered	111	12.1	2007	
THE PERSON NAMED IN				101	<u> </u>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include-copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.nors.com/winds-code with PD 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the inclusion of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application, geographic process an application, geographic process an application, geographic process and the process of the complete process and the process of the complete process of the complete process of the complete process of the process of the complete process of the process of the complete process of the comp

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE

Application Number 09/904,356 Filing Date July 12, 2001 First Named Inventor G.P. Allaway

Complete if Known

Art Unit 1648

Examiner Name Jeffery S. Parkin 43966-CB Attorney Docket Number

STATEMENT Y APPLICANT
(Use as many whites as necessary)

of 47 Sheet 5

			U. S. PATENT I		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F brown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
	<u> </u>	US-			
	-	US-		<u></u>	
	<u> </u>	US-			
		US-			<u> </u>
		US-		- · · · · · · · · · · · · · · · · · · ·	
		US-		······	
		US-			
		US-		,	
 		US-			
		US-			
		US-			
		US-			[

			GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Pateral Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Striptbir * "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T*
X		EP 114826 AZ	10-24-2001			
7		EP 1148127 A2	10-24-2001			
		EP 1149582 &2	10-31-2001			
		EP 1199360 A2	04-24-2002			
		EP 14820 A1	12-01-2004			
k .		EP 0815137	12-12-1996			

Examiner Signature		Date Considered	h/	121	200	
*EXAMINER	initially reference could like a whether or not citation is in conformance with MPEP 609. Dre	w line through	citation if	not in co	nformanée an	7~

*EXAMINER: Initially reference controlled whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this fear, with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.sp.go.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard S7.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard S7.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.
This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application (epsitedentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and followiting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to example the this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petern and Trademark Office, P.O. Box 1655/Qexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Rip. Epx 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Substitute for form 1449/PTO	Complete if Known				
	Application Number	09/904,356	_		
INFORMATION DISCLOSURE	Filing Date	July 12, 2001			
	First Named Inventor	G.P. Allaway			
STATEMENT BY APPLICANT	Art Unit	1648			
(Use as maily allects as necessary)	Examiner Name	Jeffery S. Parkin			

Sheet	6	of 47		At	omey l	Docket Number	43966-CI	<u> </u>	ノ
			11 Q DA	TENT DO	CHIME	ите			
Examiner Initials*	Cite No.1	Doeyment Number	Dodyment Number Publication Dat MM-DD-YYYY		. Name of Patentee or		Pages, Columns, Lines, Who Relevant Passages or Relev Figures Appear	ere rant	
		Number-Kind Code ^{2 (F troom)} US-	 					rigures Appear	
-		US-	 						
		US-	 	 					
		US-	<u> </u>			•			
		US-	 						
		US-	·			······································		,	
		US-	1						
		US-							
		US-							
		US							
		US-							
		US							
		US-							
		US-							
		US-	<u> </u>			······································			
		US- US-	ļ			· · · · · · · · · · · · · · · · · · ·			
		US-	 						
		US-	 						
			<u></u>						
			FOREIGN			MENTS			
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publicate Date MM-DD-Y		Name of Pat Applicant of Cite		Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	₽
		Country Code ³ Number ⁴ Kind Code ³ (# kr	тожп)	12-27-1	997			ļ	┢
0						· · · · · · · · · · · · · · · · · · ·			Г

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ³ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Ta
7		CA 2216990	12-27-1997			
)						
	L					Щ
		*				-
	 					<u> </u>
		<u> </u>			<u> </u>	نــــا

*EXAMINER: Initial if reference coal series, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this formation next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.stoff.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indigation of the year of the reign of the Emperor must proceed the serial number of the patent document. 'Vinid of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Date

Considered

Examiner

Signature

Trainstation is artiached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and confident the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1459 Algorithms for Patents, P.O. Box 1459 Algorithms (VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

43966-CB

Approved for use through 09/30/20/7. OMB 06/51-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO

Application Number 09/904,356 INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffery S. Parkin

Attorney Docket Number

47

of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	No.1	Include Tame of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
X		PCT international Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
		PCT international Search Report issued July 5, 1997 for International Application Publication No. WO 98/56421	
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	
		PCT International Search Report issued September 12, 1998 for International Application Publication No. WO 98/56421	
		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
		PCT laternational Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT laternational Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
6		PCT International Preliminary Examination Report issued January 27, 2000 for International Application Publication No. WO 98/56421	

	 		<u> </u>
Examiner	Date		T
Signature	Considered	VILL	2/2007

[&]quot;EXAMINER: Initial if reference confidences whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and fict considered. Include copy of this form with pert communication to applicant.

1 Applicant's unique citation designation and provided the communication is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete is form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Algrangia, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007, OMB 0651-0031

	Substitute for form 1449/PTO				of Information unless it contains a valid OMB control nur Complete If Known	
02000				Application Number	09/904,356	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001	
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many sh		ecces and	Art Unit	1648	
	lose as many an		, oc. 000001 y/	Examiner Name	Jeffery S. Parkin	
Sheet	8	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
8		PCT International Preliminary Examination Report issued July 10, 1998 for International Application Publication No. WO 97/37005	
		PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
	·	PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
		PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Supplementary Partial Search Report issued February 19, 2003 for European Patent Application No. 98931261.6	
+		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	

	 		<u> </u>	A
Examiner	Date			
Signature	Considered	N	עז	2007
			_	00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance/and not considered, Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007, OMB 0651-0031 redemark Office; U.S. DEPARTMENT OF COMMERCE

	nder the Paperwo		ct of 1995, no persons a		of information unless it contains a valid OM Complete If Known	
Subsuit	ate for form 1445	P10		Application Number	09/904,356	
INF	ORMATI	ION DIS	CLOSURE	Filing Date	July 12, 2001	
STA	ATEMEN	IT BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(llen ne me	ny sheets as n		Art Unit	1648	uly 12, 2001 .P. Allaway 648
	(Vat da mei	ny sa odia aa n	10C038#17/	Examiner Name	Jeffery S. Parkin	
Sheet	9	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
	-	European Supplementary Search Report issued March 6, 2002 for European Patent Application No. 97917856.3	
		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	
		April 21, 2006 Supplementary European search report under Article 157(2) (a) in connection with European Application No. 03 713 632.2	
		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
b		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	

Examiner	 Date	T	7
Signature	Considered	lils	2/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent-to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO					Complete if Known	
CODSOIL	10 10 10 11 14-01 10			Application Number	09/904,356	
INF	ORMATION	DE	CLOSURE	Filing Date	July 12, 2001	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	Also so more sha			Art Unit	1648	
(Use as many sheets as necessary)				Examiner Name	Jeffery S. Parkin	
Sheet	10	of	47	Attorney Docket Number	43966-CB	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
2		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
)		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	
		Abaza et al. (1992). Effects Of Amino Acid Substitutions Outside An Antigenic Site On Protein Binding To Monoclonal Antibodies Of Predetermi J. Prot. Chem, 11(5):433- 443	
		Alkhatib, et al. (1996). Abstract At 3rd Conference On Retroviruses	
		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1ß Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling and Importance Virology, 234:340-348	
		Allaway, G.P., et al. (1993). Synergistic Inhibition Of HIV-1 Envelope-Mediated Cell Fusion By CD4-Based Molecules In Combination AIDS Res. Hum. Retroviruses, 9:581-587	
		Allaway, G.P., (1995). Expression And Characterization Of CD4-IgG2, A Novel Heterotetramer That Neutralizes Primary HIV Type 1 Aids Res. Hum. Retrovirus, 11:533-539	
		Amara, A., et al. (1997). HIV Coreceptor Downregulation As Antiviral Principle: SDF-La- Dependent Internalization Of The Chemokine Receptor J. Exp. Med., 186:139-146	
1		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	

Examiner	N	Date		
Signature		Considered	11/12/	2057

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this formswift next communication to applicant.

1 Applicant's unique citation designation dumber (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confideral highly governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete liss form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	der the Peperwork F		ct of 1995, no persons a	re required to respond to a collection	n of information unless it contains a valid OMB control number Complete if Known	ŗ. •
	ILO IO IOIN 14-00FI	•		Application Number	09/904,356	_
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001	
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway	_
•	(Use as many s	hosts ss :	acces and	Art Unit	1648	
(out to many those to metalize)				Examiner Name	Jeffery S. Parkin	_
Sheet	11	of	47	Attorney Docket Number	43966-CB	7

-		NON PATENT LITERATURE DOCUMENTS	<u>-</u>
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
>		Arthos, J., et al. (1989). Identification Of The Residues In Human CD4 Critical For The Binding Of HIV. Cell, 57:469-481	
		Ashorn, P.A., et al. (1990). Human Immunodeficiency Virus Envelope Glycoprotein/CD4 Mediated Fusion Of Nonprimate Cells With Human Cells. J. Virol., 64:2149-2156	
		Attanasio, et al. (1991). Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations in Nonhuman Primate Species. J. Immunol., 146:507-514	
		Baba, et al. (1998). Mechanism Of Inhibitory Effect Of Dectran Sulfate And Heparin On Replication Of Human Immunodeficiency Virus In Proc. Natl. Acad. Sci., 85:6132-6135	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives Proc. Natl. Acad. Sci., 92:5470-5474	
		Baulerle and Huttner (1987). Tyrosine Sulfation Is A Trans-Golgi-Specific Protein Modification. Cell. Biol., 105:2655-2663	
		Berger, et al. (1996). Abstract No. 002, 8 at Keystone Symposium	
	-	Berger E.A. (1997). HIV Entry And Tropism: The Chemokine Receptor Connection. AIDS, 11(Suppl.A):S3-S16	
4		Berger, et al. (1999). Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism And Disease. Ann. Rev. Immunol., 17:657-700	

Examiner	,		 	Date				
Signature		<u></u>		Considered	l ul	12	רשה	
ACMANDICO. A	141 - 4 14 6		 			_		

^{*}EXAMINER: Initial if reference considered, whicher or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, Include copy of this form with right communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached. This collection of information is required by 20 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially improvemed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. ON NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwo	ork Reduction A	ct of 1995, no persons a	re required to respond to a collection	of Information unless it contains a valid QMB control Complete If Known	d number.
Substitu	ite for form 1449	VPTO		Application Number	09/904,356	
INF	ORMAT	ION DAS	CLOSURE	Filing Date	July 12, 2001	
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway	
	/l leo pe ma	nu choete ee s	naces and	Art Unit	1648	
(Uso as many shoets as necessary)				Examiner Name	Jeffery S. Parkin	
Sheet	12	of	47	Attorney Docket Number	43966-CB	

Examiner Initials*	Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
1		Brelot, A., et al. (1997). Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity. J. Virol., 71:4744-4751	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1993). The Block To HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion In Animal Cells Expressing Human CD4 Virol., 193:483-491	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Burkly, L., et al. (1995). Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion and Infection J. Virol., 69:4267-4273	
	,	Burton, D.R., et al. (1994). Efficient Neutralization Of Primary Isolates Of HIV-1 By A Recombinant Human Monoclonal Antibody. Science, 266:1024-1027	
		Busso, et al. (1991). HIV-Induced Syncytium Formation Requires The Formation Of Conjugates Between Virus-Infected And Uninfected T-Calls In Vitro. AIDS, 5:1425-1432	
		Cammack, N. (1999). Human Immunodeficiency Virus Type 1 Entry And Chemokine Receptors: A New Therapeutic Target. Antiviral Chemistry And Chemotherapy, 10:53-62	
•		Capon, D.J., et al. (1989). Designing CD4 Immunoadhesions For AIDS Therapy. Nature, 337:525-531	

Examiner Signature Considered 1 (42 / 2 a r						
Signature Considered (1/47/27)	Examiner		Date			1
		(Considered	he	w	200

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 87 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting title completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandría, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandría, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/904,356 INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffery S. Parkin Sheet **Attorney Docket Number** 13 47 43966-CB

of

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
~		Chan, D.C., et al. (1998). Evidence That A Prominent Cavity In The Coiled Coil Of HIV Type 1 Gp41 Is An Attractive Drug Target. Proc. Natl. Acad. Sci., 95:15613-15617	
1		Chan, D.C., et al. (1998). HIV Entry And Its Inhibition. Cell, 93:681-684	
7		Charo, et al. (1994). Molecular Cloning And Functional Expression Of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Proc. Natl. Acad. Sci., 91:2752-2756	
		Chen, et al. (1997). Genetically Divergent Strains Of Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For Entry. J. Of Virol., 71(4):2705-2714	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
		Clapham, P.R., et al. (1991). Specific Cell Surface Requirements For The Infection Of CD4-Positive Cells By Human Immunodeficiency Virus Types 1 And 2 Virol., 181:703-715	
		Co, et al. (1991). Humanized Antibodies For Antiviral Therapy. Proc. Natl. Acad. Sci., 88:2869-2873	
		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	
		Combadiere, et al. (1995). Cloning And Functional Expression Of A Human J. Biol. Chem., 270, 16491-16494 (NOTE - Erratum In: J. Biol. Chem. 1995 Dec 15; 270(50):30235))	
: •		Combadiere, et al. (1996). Cloning And Functional Expression Of CC CKR5, A Human Monocyte CC Chemokine Receptor Selective For J. Leukos. Biol., 60:147-152	

Examiner	A.	Date	1	
Signature		Considered	1 4 12	2001
AFVARABLED. I				

^{*}EXAMINER: Initial if referebbe considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with east communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 97 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting title completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork		ct of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitu	ito idi lolin 1445/F1	U	•	Application Number	09/904,356	
INF	ORMATIC	N DIS	CLOSURE	Filing Date	July 12, 2001	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many	choete se c		Art Unit	1648	
	lose as many		acassay)	Examiner Name	Jeffery S. Parkin	
Sheet	14	of	47	Attorney Docket Number	43966-CB	
_	<u> </u>			L		

	·	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
8		Connor, R.I, et al., (1997). Change In Co-Receptor Use Correlates With Disease Progression In HIV-1 Infected Individuals. J. Exp. Med., 185:621-628			
)		Comier, E.G., et al. (2000). Specific Interaction Of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines With HIV-1 EnvelopeProc. Natl. Acad. Sci., 97:5762-5767			
		Crump, M.P., et al. (1997). Solution Structure And Basis For Functional Activity Of Stromal-Cell Derived Factor-1: Disassociation Of CXCR4 Activation EMBO, 16:6996-7007			
1		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc,. Boca Raton, FL., 143:QR180.4.C78			
		Cushman, M., et al. (1991). Preparation And Anti-HIV Activities Of Aurintricarboxylic Acid Fractions And Analogues: Direct Correlation Of J. Med. Chem., 34:329-337			
		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Proc. Natl. Acad. Sci., 87:6574-6578			
		Dalgleish, A.G., et al. (1984). The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus. Nature, 312:763-766			
		Dalgleish, A.G. (1995). HIV And CD26. Nature Medicine, 1:881-882			
·		De Rossi, A., et al. (1995). Synthetic Peptides From The Principle Neutralizating Domain Of Human Immunodeficiency Virus Type 1 (HIV-1) Enhance HIV-1 Virology, 184:187-196			
4		Dean, M., et al. (1996). Genetic Restriction Of HIV-1 Infection And Progression To AIDS By A Deletion Allele Of The CKR5 Structural Gene. Science, 273:1856-1862			

		•				
Examiner	T		Date			
Signature	<i>\</i>		Considered	11	12	7007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with riext communication to applicant.

considered. Include copy of this form with rest communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 87 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially in-governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting tits completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete If Known Substitute for form 1449/PTO **Application Number** 09/904,356 INFORMATION DISCLOSURE **Filing Date** July 12, 2001 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffery S. Parkin

Attorney Docket Number

43966-CB

Sheet

15

47

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	_
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/		De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of Proc. Natl. Acad. Schi., 89:5286-5290	
1		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deen, K.C., et al. (1988). A Soluble Form Of CD4(T4) Protein Inhibits AIDS Virus Infection. Nature, 331:82-84	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Deng, X., et al. (1999). A Synthetic Peptide Derived From Human Immunodeficiency Virus Type 1 Gp120 Down-Regulates The Expression And Function Blood, 94(4):1165-1173	
		Dettin, et al. (2003). CCR5 N-Terminus Peptides Enhance X4 HIV-1 Infection By CXCR4 Up-Regulation. Biochem. Biophys. Res. Commun., 307(3):640-646	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta Med. Croatica, 50:163-168	
		Ditzel, et al. (1998). The CCR5 Receptor Acts As An Alloantigen In CCR5∆32 Homozygous Individuals: Identification Of Chemokine And Proc. Natl. Acad. Sci., 95(9):5241-5245	
4		Donzella, G.A., et al. (1998). AMD3100, A Small Molecule Inhibitor Of HIV-1 Entry Via The CXCR4 Co-Receptor. Nat. Med., 4:72-77	

Examiner	1		Date				
Signature		-	Considered	Vi.	12	2007	

*EXAMINER: Initial if regrence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trade

	te for form 1449/PT				Complete if Known	MB control number.
		_		Application Number	09/904,356	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many s	-ht		Art Unit	1648	····
	(OSC 45 (BEILY E		140000017/	Examiner Name	Jeffery S. Parkin	
Sheet	16	of	47	Attorney Docket Number	43966-CB	

<u>. </u>		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\mathcal{V}_{-}		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
V		Doranz, B.J., et al. (1997). Two Distinct CCR5 Domains Can Mediate Co-Receptor Usage By Human Immunodeficiency Virus Type 1. J. Virol., 71:6305-6314	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
		Dragic, T.V., et al. (1995). Proteinase-Resistant Factors In Human Erythrocyte Membran Mediated CD-4 Dependent Fusion With Cells Expressing J. Virol., 69:1013-1018	
		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	
		Dragic, T.V., et al. (1998). Amino-Terminal Substitutions In The CCR5 Coreceptor Impair Gp120 Binding And Human Immunodeficiency Virus Type 1 Entry. J. Virol., 72(1):279-285	
		Dragic, et al. (2000). A Binding Pocket For A Small Molecule Inhibitor Of HIV-1 Entry Within The Transmembrane Helices Of CCR5. Proc. Natl. Acad. Sci., 97(10):5639-5644	
		Eckert, D.M., et al. (1999). Inhibiting HIV-1 Entry: Discovery Of D-Peptide Inhibitors That Target The gp41 Coiled-Coil Pocket. Cell, 99:103-115	
		Eugen-Olsen, J., et al. (1997). Heterozygosity For A Deletion In The CKR-5 Gene Leads To Prolonged AIDS-Free Survival And Slower CD4 T-Cell AIDS, 11:305-310	
•		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	-

Examiner	10	Date		
Signature		Considered	11/12	2/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with night communication to applicant.

1 Applicant's unique citation designation sumber (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by \$7 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the configeration form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwor		ct of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Judoutu	10101011111111111	-10		Application Number	09/904,356	
INF	ORMATI	ON DES	CLOSURE	Filing Date	July 12, 2001	
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(1ton on			Art Unit	1648	
	(Use as man	ly sheets as n	ecessary)	Examiner Name	Jeffery S. Parkin	
Sheet	17	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS			
Examine Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
~	7	Farzan, M., et al. (1998). A Tyrosine-Rich Region In The N-Terminus Of CCR5 Is Important For Human Immunodeficiency Virus Type 1 Entry And MediatesJ. Virol., 72:1160-1164			
1		Farzan, M., et al. (1999). Tyrosine Sulfation Of The Amino-Terminus Of CCR5 Facilitates HIV-1 Entry. Cell, 96:667-676			
		Farzan, M., et al. (2000). A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 J. Biol. Chem., 275:33416-33521			
		Feng, et al. (1996). Abstract No. 116,21 at Keystone Symposium			
		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877			
		Ferrer, M., et al. (1999). Selection Of gp-41 Mediated HIV-1 Cell Entry Inhibitors From Biased Combinatorial Libraries Of Non-Natural Nature. Struct. Biol., 6:953-959			
		Flexner, C. and Hendrix, C. (1997). "Pharmacology Of Antiretroviral Agents", in AIDS: Bio, 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493			
		Fouts, T.R., et al. (1997). Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies J. Virol., 71:2779-2785			
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128			
+		Fradd, F. and Mary, M.E. (1989). AIDS Vaccines: An Investor's Guide, Shearman Lehaman Hutton. P. 10:(Fig. 2)			

Examiner		Date		
Signature	1	Considered	1412	201

*EXAMINER: Initial if re-frence considered. Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiafity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ur	nder the Peperwo	rk Reduction A	ct of 1995, no persons a	re required to respond to a collection	o of Information unless it contains a valid Of Complete if Known	MB control number.
Substitute for form 1449/PTO				Application Number	09/904,356	
INF	ORMATI	ON DE	CLOSURE	Filing Date	July 12, 2001	· · · · · · · · · · · · · · · · · · ·
STA	ATEMEN	T BY A	PPLICANT	First Named Inventor	G.P. Allaway	· · · · · ·
	(Man on man	ny sheets as (Art Unit	1648	
	(cea sa mar	iy əned is eş i	1 00033817)	Examiner Name	Jeffery S. Parkin	
Sheet	18	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		Furuta, R.A., et al. (1998). Capture Of An Early Fusion-Active Conformation Of HIV-1 gp41. Nature Struct. Biol., 5(4):276-279	
		Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gauduin, M.C., et al. (1996). Effective Ex Vivo Neutralization Of Plasma HIV-1 By Recombinant Immunoglobulin Molecules. J. Virol., 70:2586-2592	
		Gauduin, M.C., et al. (1997). Passive Immunization With A Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge By Primary Nature Medicine, 3:1389-1393	
		Ghorpade A., et al. (1998). Role Of The Beta-Chemokine Receptors CCR3 And CCR5 in Human Immunodeficiency Virus Type 1 Infection Of Monocytes And J. Virol, 72:3351-3361	
		Golding, H., et al. (1992). LFA-1 Adhesion Molecules Are Not Involved In The Arly Stages Of HIV-1 Env-Mediated Cell Membrane Fusion. AIDS Res. Hum. Retroviruses, 8:1593-1598	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal J. Exp. Med., 181:631-640	
		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Grene, et al. (2001). Anti-CCR5 Antibodies In Sera Of HIV-Positive Individuals. Human Immunol., 62(2):143-145	
1		Harrington, R.D. and Geballe, A.P. (1993). Cofactor Requirement For Human Immunodeficiency Virus Type 1 Entry Into A CD4-Expressing Human Cell Line. J. Virol., 67:5939-5947	

Examiner			Date		•		_
Signature	l		Considered	121	12	200	
*EYAMINED: I-	itial II a	plannes considered subother or not citation is in conformance with MDCD CO	O. Demutine therein a	4-41			_

considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) en application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting this collected application form to the USPTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Un	der the Paperworl	Reduction A	ct of 1995, no persons a		of information unless it contains a valid ON	
			··-		Complete If Known	
0				Application Number	09/904,356	
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	July 12, 2001	
STA	Substitute for form 1449/PTO NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	PPLICANT	First Named Inventor	G.P. Allaway		
		Art Unit	1648			
	(USO de men	y 21100C3 43 1	acossa: y/	Examiner Name	Jeffery S. Parkin	
Sheet	19	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		Hattori, T., et al. (1989). Involvement Of Tryptase-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
\	-	Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
		He, Jianglin, et al. (1997). CCR3 And CCR5 Are Co-Receptors For HIV-1 Infection Of Microglia. Nature, 385:645-649	
		Heath, et al. (1997). Chemokine Receptor Usage By Human Eosinophils. The Importance Of CCR3 Demonstrated Using An Antagonistic Monoclonal J. Clin. Invest., 99:178-184	
		Heidenreich, et al. (1995). Application Of Antisense Technology To Therapeutics. Mol. Med. Today, 1:128-133	
		Hildreth, et al. (1989). Involvement Of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation. Science, 244:1075-1078	
		Hill, C.M., et al. (1998). The Amino Terminus Of Human CCR5 Is Required For Its Function As A Receptor To Diverse Human And Simian Immunodeficiency Virology, 248:357-371	
		Hirata, Y. (1989). Characterization Of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies. J. Immun., 2900-2906	
		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	
•		Hwang, S.S., et al. (1991). Identification Of The Envelope V3 Loop As The Primary Determinant Of Cell Tropism In HIV-1. Science, 253:71-74	

Examiner	Date			
Signature	Considered	W	12	200
PEVAMINED. I	'11 LADED 400 D			

whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 09/904,356

Filling Date July 12, 2001

First Named Inventor G.P. Allaway

Art Unit 1648

Examiner Name Jeffery S. Parkin

Attorney Docket Number

43966-CB

Sheet

20

47

-	1 04	NON PATENT LITERATURE DOCUMENTS	
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ť
2		Jacobson, J.M., et al. (1993). Passive Immunotherapy In The Treatment Of Advanced Human Immunodeficiency Virus Infection. J. Infect. Dis., 168:298-305	
		Jacobson, J., et al. (1999). Results Of A Phase, A Novel Inhibitor Of HIV Entry. Abstracts Of The 39th Interscience Conference On Antimicrobial Agents And Chemotherapy 14	
T		Ji, H., et al. (1999). Inhibition Of Human Immunodeficiency Virus Type 1 Infectivity By The gp41 Core: Role Of A Conserved Hydrophobic Cavity In J. Virol., 73:8578-8586	
		Jiang, S., et al. (1993). HIV-1 Inhibition By A Peptide. Nature, 365:113	
		Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
		Karwowska, S., et al. (1991). Passive Immunization For The Treatment And Prevention Of HIV Infection. Biotech. Therap., 2:31-48	
		Katinger, H. (1994). Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1. Antibiot. Chemother., 46:23-37	
		Kilby, J.M., et al. (1998). Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry. Nature Med., 4:1302-1307	
		Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
4		Konigs, C., et al. (2000). Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Eur. J. Immnol., 30(4):1162-1171	

Examiner	N		 Date				
Signature		\sim	Considered	WI	2	2107	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation aunitor (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 3° CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiaffly is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete finis form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Peternt and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Discollection of information unless it contribute a until 0.000 contribute.

INFORMATION DISCLOSURE FIN		Complete if Known			
0				Application Number	09/904,356
INF	ORMATION	1 D15	CLOSURE	Filing Date	July 12, 2001
STA	INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Use as many sheets as necessary)	PPLICANT	First Named Inventor	G.P. Allaway	
		accepted.	Art Unit	1648	
	(Coo as many an		iocossary)	Examiner Name	Jeffery S. Parkin
Sheet	21	of	47	Attorney Docket Number	43966-CB

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\bigvee		Konishi, K., et al. (2000). Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Chem. Pharm. Bull., Tokyo, 48(2):308-309	
,		Koup, R.A., et al. (1996). Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice. Immunology, 8:263-268	
		Kwong, P.D. et al. (1998). Structure Of An HIV gp120 Envelope Glycoprotein in Complex With The CD4 Receptor And Neutralizing Human Antibody. Nature, 393:648-659	
		Laal, S., et al. (1994). Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies. J. Virol., 68:4001-4008	
		LaCasse, R.A., et al. (1999). Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV. Science, 283:357-362	
		Lee, B., et al. (1999). Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In J. Biol. Chem., 9617-9626	
		Lehner, et al. (2001). Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian Journal Of Immunology, 166(12):7446-7455	
·		Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
		Li, A., et al. (1997). Synergistic Neutralization Of Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1 AIDS Res. Hum. Retroviruses, 12:647-56	
1		Li, A.H., et al. (1998). Synergistic Neutralization Of Simian-Human Immunodeficiency Virus SHIV-vpu+ By Triple And Quadruple Combination Of Human J. Virol., 72:3235-3240	

				<u> </u>
Examiner	Date			
Signature	Considered	l	12	2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by \$7 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including eithering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the take 2 hours to complete, including athering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		CA OF 1995, NO DETROITS BE	Complete If Known		
				Application Number	09/904,356	
INFORMATION DESCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Filling Date First Named Inventor Art Unit Examiner Name	July 12, 2001					
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	G.P. Allaway	
	(lee ee many cha		anner and	Art Unit	1648	
	(Use as many sheets as necessary)			Examiner Name	Jeffery S. Parkin	
Sheet	22	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\mathcal{N}		Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A Primary Isolate, J. Virol., 70(9):6437-6441	
1		Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237	
		Mack, M., et al. (1998). Aminooxypentane-RANTES Induces CCR5 Internalization But Inhibits Recycling: A Novel Inhibitory Mechanisms Of HIV J. Ex. Med., 187:1215-1224	
		Mackay, C.R. (1996). Chemokine Receptors And T Cell Chemotaxis. J. Exp. Med., 84:799-802	
		Maddon, P.J., et al. (1986). The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain. Cell, 47:333-348	
		Markosyan, R.M., et al. (2002). The Mechanism Of Inhibition Of HIV-1 Entry Env-Mediated Cell-Cell Fusion By Recombinant Cores Of gp41 Ectodomain. Virology, 302:174-184	
		McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is Both Cell Type J. Virol., 71:1692-1696	
		Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
		Mohan, P., et al. (1992). Sulfonic Acid Polymers As A New Class Of Human Immunodeficiency Virus Inhibitors. Antiviral Res., 18:139-150	
•		Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	

				<u> </u>
Examiner	Date			
Signature	Considered	ti l	10,1	700

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance with a considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the corepleted application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	ute for form 1449/PT	<u> </u>	· · · · · · · · · · · · · · · · · · ·		Complete if Known	
Gusan				Application Number	09/904,356	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit (Use as many shoots as necessary)	July 12, 2001					
ST	(Use as many sheets as necessary)	PPLICANT	First Named Inventor	G.P. Allaway		
			Art Unit	1648		
	(Use as many	aneets as n	ecessary)	Examiner Name	Jeffery S. Parkin	
Sheet	23	of	47	Attorney Docket Number	43966-CB	

Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		Mosier, D.E. (1990). Immunodeficient Mice Xenografted With Human Lymphoid Cells: New Models For In-Vivo Studies Of Human Immunobiology And J. Clin. Immuno., 10(4):185-191	
1		Nagasawa, et al. (1994). Molecular Cloning And Structure Of A Pre-B-Cell Growth-Stimulating Factor. Proc. Natl. Acad. Sci., 91:2305-2309	
		Nagashima, K.A., et al. (2001). Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 And T-20 Are Potently Synergistic In Blocking J. Infect. Dis., 183:1121-1125	
,		Nakano, T., et al. (1995). Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca2+ mobilizing growth J. Biol. Chem., 270(11):5702-5705	
		Neote, et al. (1993). Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell, 72:415-425	
		Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	
		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
		Olson, et al., (1999). Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding and CC-chemokine Activity of Monoclonal J. Virol., 73:4145-4155	
4		Opperman, (2004). Chemokine Receptor CCR5: Insights Into Structure, Function, And Regulation. Cell. Signal., 16:1201-1210	

Examiner		•	Date	е				_
Signature			Con	sidered	110	12	200	7

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PTO				Complete if Known	1
010000				Application Number	09/904,356	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001	1.
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway	
	Afen ne manu ei			Art Unit	1648	
(Use as many sheets as necessary)				Examiner Name	Jeffery S. Parkin	
Sheet	24	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Parren, et al. (2001). Antibody Protects Macaques Against Vaginal Challenge With A Pathogenic R5 Simian/Human Immunodeficiency Virus At Serum J. Virol., 75:8340-8347	
- (Partidos, C., et al. (1992). The Effect Of Orientation Of Epitopes On The Immunogenicty Of Chimeric Synthetic Peptides Representing Molecular Immunology, 29(5):651-658	
		Poignard, P., et al. (1999). Neutralizing Antibodies Have Limited Effects On The Control Of Established HIV-1 Infection In-Vivo. Immunity, 10:431-438	
		Posner, M.R., et al. (1993). Neutralization Of HIV-1 By F105, A Human Monoclonal Antibody To The CD4 Binding Site Of gp120. J. Acq. Immune Defic. Synd., 6:7-14	
		Power, et al. (1995). Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor Cdna From A Human Basophilic Cell Line. J. Biol. Chem., 270:1811-1815	
		Proudfoot, et al. (1996). Extension Of Recombinant Human RANTES By The Retention Of The Initiating Methlonine Produces A Potent Antagonist. J. Biol. Chem., 271:2599-2603	
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246-256	
		Queen, et al. (1989). A Humanized Antibody That Binds To The Interleukin 2 Receptor. Proc. Natl. Acad. Sci, 86:10029-10033	
7		Rabut, G.E., et al. (1991). Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of J. Virol., 72:3464-3468	

Examiner Signature	0	~	Date Considered)(12	2007	
PEVALUNED. L	sidel if subsequence	analala and subathan as not citation to in confirms	was with MIDEO COO. Down line through a	10 AT 1 14		Tarana and and	-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy for all so form with next communication to applicant.

Applicant's unique citation designation huraber (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by §7 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will velocity depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissionar for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	te for form 1449/PTO		z or 1995, no persons a	Complete if Known				
()				Application Number	09/904,356			
INF	ORMATION	DIS	CLOSURE	Filing Date	July 12, 2001			
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway			
	(Use as many she	a ta aa m		Art Unit	1648			
	(USE as many and	913 E\$ //	ocesaery)	Examiner Name	Jeffery S. Parkin			
Sheet	25	of	47	Attorney Docket Number	43966-CB			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W		Raport, C.J., et al. (1998). Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, J. Biol. Chem., 271:1761-1766	
U		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Rodriguez, G., et al. (1995). Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cel Surface Heparin Sulfate Proteoglycans J. Virol., 69:2233-2239	
		Rucker, et al. (1996). Regions In Beta-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity. Cell, 87:437-446	
		Ruffing, et al. (1998). CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Calls. Cell. Immunol., 160:160-168	
		Rudikoff, et al. (1982). Single Amino Acid Substitution Altering Antigen-Binding Specificity. Proc. Natl. Acad. Sci., 79:1979-1983	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
4		Sandberg, J. (1995). Developmental Pharmacology And Toxicology Of Anti-HIV Therapeutic Agents: Dideoxynucleosides. FASEB J., 9:1157-1163	

Examiner \	Date		
Signature	Considered	11/12/	2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation in conformance and not considered. Include copy of this form with sext communication to applicant.

Considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting lite completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Onder the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO			ct of 1995, no persons a	re required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Oubsuit	310 101 101111 144317	•		Application Number	09/904,356
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	July 12, 2001
STA			PPLICANT	First Named Inventor	G.P. Allaway
	NFORMATION DISCLOSUR TATEMENT BY APPLICAN (Use as many shoots as necessary)			Art Unit	1648
	(USO ES MAII)	7 8/100 LB LB 1	ACCUSSALY/	Examiner Name	Jeffery S. Parkin
Sheet	26	of	47	Attorney Docket Number	43966-CB

Evamina	- 10%	NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		Sato, et al. (1992). Anti-Cd7 Reagents Inhibit HIV-1 Induced Syncytium Formation. International Conference on AIDS, 8I. PA5 PoA 2017	
1		Sato, et al. (1994). Identification Of CD7 Glycoprotein As An Accessory Molecule in HIV-1 Mediated Syncytium Formation And Cell Free Infection. J. Immunol., 152:5142-5152	
		Sato, et al. (1995). A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV Compounds In Mice. Antivir. Res., 27:151-163	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):1259-1265	
		Schanberg, et al. (1995). Characterization Of Human CD7 Transgenic Mice. J. of Immunol., 155:2407-2418	
		Schols, D., et al. (1990). Dextran sulfate and other olyanionic anti-HIV compounds specifically interact with the viral gp120 Glycoprotein Expressed Virology, 175:556-561	
		Schols, D., et al. (1991). Selective Inhibitory Activity Of Polyhydroxycarboxylates Derived From Phenolic Compounds Against Human J. Acq. Immune Defic. Synd., 4:677-685	
		Schols, D., et al. (1999). CD26-Processed RANTES(3-68), But Not Intact RANTES, Has Potent Anti-HIV-1 Activity. Antiviral Res., 30:175-187	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
4		Sommerfelt, M.A., et al. (1995). Intercellular Adhesion Molecule 3, A Candidate Human Immunodeficiency Virus Type 1 Co-Receptor On Lymphoid J. Gen. Virol., 76:1345-1352	

Examiner \	Date		
	2	1 1	10.5
Signature / \	Considered	ロルハス	(ω)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with Rext communication to applicant.

1 Applicant's unique citation designation nutriber (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 87 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including athering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					of information unless it contains a valid OMB control number. Complete if Known
			Application Number	09/904,356	
Application Number 09/904,356 INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 Examiner Name Jeffery S. Parkin					
STA	STATEMENT BY APPLICAN	PPLICANT	First Named Inventor	G.P. Allaway	
	(Uso as many shoets as necessary)		ecareand	Art Unit	1648
	1000 as many and		ocossary)	Examiner Name	Jeffery S. Parkin
Sheet	27	of	47	Attorney Docket Number	43966-CB

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
Y		Steinberger, P., et al. (2000). Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody. J. Biol. Chem., 275:36073-36078	
		Stewart, G.J. (1997). Increased Frequency Of CCR-5∆32 Heterozygotes Among Long-Term Non-Progressors With HIV-1 Infection. AIDS, 11:1833-1838	
		Strizki, J.M., et al. (1997). A Monoclonal Antibody (12G5) Directed Against CXCR4 Inhibits Infection With The Dual-Tropic Human Immunodeficiency J. Virol., 71:5678-5683	
		Su, et al. (1996). Preparation Of Specific Polyclonal Antibodies To A C-C Chemokine Receptor, CCR1, And Determination Of CCR1 Expression On J. Leukos. Biol., 60:658-666	
		Thali, M., et al. (1992). Cooperativity Of Neutralizing Antibodies Directed Against The VS And CD4 Binding Regions Of The Human J. Acq. Immune. Defic. Synd., 5:591-599	
		Tilley, S.A., et al. (1991). Potent Neutralization Of HIV-1 By Human And Chimpanzee Monoclonal Antibodies Directed Against Three Sixieme Colloque Des Cent Gardes., 211-216	
		Tremblay, et al. (2000). Strong in Vitro Synergy Observed Between The Fusion February 7th, 2000 Conference on Retroviruses and Opportunistic Infections, abstract 500	
		Tremblay, et al. (1999). Strong In Vitro Synergy Between The Fusion Inhibitor T-20 And The CXCR4 Blocker Journal of Acquired Immune Deficiency Syndromes, 25(2):99-102	
		Trkola, A., et al. (2001). Potent, Broad-Spectrum Inhibition Of Human Immunodeficiency Virus Type 1 By The CCR5 Monoclonal Antibody PRO 140. J. Virol., 75:579-588	
		Trkola, A., et al. (1999). Cross-Clade Neutralization Of Primary Isolates Of Human Immunodeficiency Virus Type 1 By Human Monoclonal Antibodies J. Virol., 73(5):4145-4155	

					/
Examiner I	· ·	Date			
				1. 1	
Signature		l Considered	1 4 1	112.1	2097
					<i>w</i>
PEVALUATED. In	taled to the second of the sec				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with sext communication to applicant.

Considered. Include copy of this form with facts communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 87 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ider the Paperwork I		ct of 1995, no persons a	re required to respond to a collection	of information unless it contains a valid O Complete if Known	MB control number.
Subsum	Ne for form 1445/P1	U		Application Number	09/904,356	
INF	ORMATIC	N DIS	CLOSURE	Filing Date	July 12, 2001	
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many	ahaata aa a	4	Art Unit	1648	
٠	(USB 85 many	enegus as n	1000334/7/	Examiner Name	Jeffery S. Parkin	
Sheet	28	of	47	Attorney Docket Number	43966-CB	

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Y		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
)		Trkola, A., et al. (1998). Neutralization Sensitivity Of Human Immunodeficiency Virus Type 1 Primary Isolates To Antibodies And CD40 based Reagents J. Virol., 72:1876-1885	
		Tulip, W.R., et al. (1992). Crystal Structures Of Two Mutant Neraminidase-Antibody Complexes With Amino Acid Substitutions In The Interface. J. Mol. Biol., 227:149-159	
		Valentin, et al. (1990). The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncyia Formation In Monocytoid And T Cells. J. of Immunology, 144:934-937	
		Valenzuela, A., et al. (1997). Neutralizing Antibodies Against The V3 Loop Of Human Immunodeficiency Virus Type 1 Block The CD4-Dependent And J. Virol., 71(11):8289-8298	
		Vijh-Warrier, S., Pinter, A., Honnen, W.J., and Tilley, S.A. (1996). Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By A J. Virol., 70:4466-4473	
		Vila-Coro, et al. (2000). HIV-1 Infection Through The CCR5 Receptor Is Blocked By Receptor Dimerization. Proc. Natl. Acad. Sci., 97(7):3388-3393	
		Vita, C., et al. (1999). Rational Engineering Of A Mini-Protein That Reproduces The Core Of The CD4 Site Interacting With HIV-1 Proc. Natl. Acad. Sci. 96:13091-13096	
		Wang, et al. (1994). Deletion Of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 and gp120-Specific Antibodies From AIDS Eur. J. Immunol., 24:1553-1557	
1		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	

Examiner	Date			
Signature	Considered	Y	12	2007
AEW A 8 818 1EE	14 110 - 1			

^{*}EXAMINER: Initial if regerence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with sext communication to applicant.

considered. Include copy of this form with sext communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 97 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting lits complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			Complete if Known		
0000000				Application Number	09/904,356
INF	ORMATION	DIS	CLOSURE	Filing Date	July 12, 2001
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she	-d		Art Unit	1648
	(Ose as many and	413 43 11	ocessary)	Examiner Name	Jeffery S. Parkin
Sheet	29	of	47	Attorney Docket Number	43966-CB

	1 -:-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
8	 	Wild, C., et al. (1992). A Synthetic Peptide Inhibitor Of Human Immunodeficiency Virus Replication: Correlation Between Solution Proc. Natl. Acad. Sci., 89:10537-10541	
)		Wild, C., et al. (1993). A synthetic peptide from HIV-1 Gp41 Is A Potent Inhibitor Of Virus Mediated Cell-Cell Fusion. AIDS Res. Humn. Retroviruses, 9:1051-1053	
		Wild, C., et al. (1994). Peptides Corresponding To A Predictive Alpha-Helical Domain Of Human Immunodeficiency Virus Type 1 gp41 Are Proc. Natl. Acad. Sci., 91:9770-9774	
		Wild, C., et al. (1995). The Inhibitory Activity Of An HIV Type 1 Peptide Correlates With Its Ability To Interact With A Leucine AIDS Res. Hum. Retroviruses,11:323-325	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, et al. (1997). Interaction Of Chemokine Receptor CCR5 With Its Ligands: Multiple Domains For HIV-1 gp120 Binding And A Single Domain J. Exper. Med., 186(8):1373-1381	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gpl20 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yamagami, et al. (1994). cDNA Cloning And Functional Expression Of Human Monocyte Chemoattractant Protein 1 Receptor. Biochem. Biophys. Res. Commun., 212:1156-1162	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For Future J. Enzyme Inhibit., 6:99-11	
•		Ylisastigui, L., et al. (1998). Synthetic Full Length And Truncated RANTES Inhibit HIV-1 Infection Or Primary Macrophages. AIDS, 12:977-984	

Signature Considered 11 2 2007	Examiner	$\overline{\wedge}$	 	 Date				
	Signature			Considered	126	12	2007)

*EXAMINER: Initial if reflyence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with Rext communication to applicant.

considered. Include copy of this form with first communication to applicant:

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentifility is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting life completed application form to the USPTO. There will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PTO				Complete if Known
0000000	101011011111111111111111111111111111111			Application Number	09/904,356
INF	ORMATION	DIS	CLOSURE	Filing Date	July 12, 2001
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she			Art Unit	1648
	(Use as meny sne	70 H H H T	r ocussary)	Examiner Name	Jeffery S. Parkin
Sheet	30	of	47	Attorney Docket Number	43966-CB

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	ł .
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Y		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
1		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	i
		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner Signature		Date Considered	11/12	2007
PEVALUED. I-	ided if reference as addressed whether as not similar in its section as a site. MISTO CO.	O. Daniella a Abanesa		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	ider the Paperwork R		ct of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
, Subsuit	Ale for form 1440/FTV	•		Application Number	09/904,356		
INF	ORMATIO	N DIS	SCLOSURE	Filing Date	July 12, 2001	_	
STA	STATEMENT BY APPLICANT			First Named Inventor	G.P. Allaway		
	(I lee as many s	chaoto so :	nace a cond	Art Unit	1648		
(Use as many sheets as necessary)			rocessary)	Examiner Name	Jeffery S. Parkin		
Sheet	31	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
2		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3			
1		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3			
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3			
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601			
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601			
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601			
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601			
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284			
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284			
8		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284			

Examiner	Date			
Signature	Considered	It !	12	2007

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include oxely of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/904,356 INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffery S. Parkin **Attorney Docket Number** Sheet 32 47 of 43966-CB

Function -	LOW	NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
8		April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284		
Ţ	,	September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284		
		December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284		
		April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963		
		December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963		
		February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356		
		May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356		
		October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356		
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356		
		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356		

			_		
Examiner \(\lambda \)	Date	. 1	- 1		
Signature	Considered	hle	2/	2007	
	001.0100100			<u> </u>	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with rest communication to applicant.

1 Applicant's unique citation designation-nustiber (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by \$7 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting this collection form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	ite for form 1449/PTO		A 04 1000, 110 paracris as	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
0	10 10 10 11 17 10 10			Application Number	09/904,356		
INF	ORMATION	I DIS	SCLOSURE	Filing Date	July 12, 2001		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	G.P. Allaway		
	(Use as many sh		accessed.	Art Unit	1648		
Tool to many anothe 2 meetically				Examiner Name	Jeffery S. Parkin		
Sheet	33	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	er Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
4	^	July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356	
Ĭ		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
1		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
4		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
•		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
1		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

	 				<u>* </u>
Examiner		Date		I	
Signature		Considered	10	112	2001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference Considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperworl		ct of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Jousan	ite to to in 144ar	10		Application Number	09/904,356		
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	July 12, 2001		
STA	STATEMENT BY APPLICANT			First Named Inventor	G.P. Allaway		
	(lipo na man	v ekonte se s	accessed.	Art Unit	1648		
(Uso as many shorts as necessary)			ioconsa/y/	Examiner Name	Jeffery S. Parkin		
Sheet	34	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
1	7	August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
1		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
J		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

l Examiner I	Date	1	
0:		11/10	1711
Signature	Considered	111112	-1 WD 1
CVARABIED. In			

^{*}EXAMINER: Initial liftererence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with sext communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	te for form 1449/PT		CC 04 1500, 110 persons as	are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Jubsuit	2010/10/11/14/07	•		Application Number	09/904,356		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001		
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway		
	/lies se manu e	rhoote ee r	ecessaria.	Art Unit	1648		
(Use as many sheets as necessary)				Examiner Name	Jeffery S. Parkin		
Sheet	35	of	47	Attorney Docket Number	43966-CB	J	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
In		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
7		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Examiner			Date				•
Signature		h_	Considered	h	12/	2007	
PEVALAINED: In	Mal March	the second substitute of the second substitution in its section of the second substitution in the seco	C. Daniellan therein	4-41-14		4	-

*EXAMINER: Initial Threference considered, whether or not citation is in conficensidered. Include copy of this form with next communication to applicant. e considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not

considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO		Complete if Known			
Oussile	10 10 10 10 10 10			Application Number	09/904,356
INF	ORMATION	DIS	CLOSURE	Filing Date	July 12, 2001
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she		accordant	Art Unit	1648
	(Use as many sine		ocused y/	Examiner Name	Jeffery S. Parkin
Sheet	36	of	47	Attorney Docket Number	43966-CB

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
		December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
V		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

Examiner Signature	Ω	Date Considered	11/12	1200
O.g. a.u.u		00:10:00:00	11110	1 20
ACVABABICO. I-	is at it and a second and a second with the second and a second and a second and a second and a second as the seco	3 000 Dec. Es-Abs	IA - A! 4 1 4 1	14

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation (esignation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/P			re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
			•	Application Number	09/904,356		
INF	ORMATIC	ON DIS	SCLOSURE	Filing Date	July 12, 2001		
STA	ATEMENT	ΓBY A	PPLICANT	First Named Inventor	G.P. Allaway		
	(lee as mam	, choote se :	140000000	Art Unit	1648		
(Use as many sheets as necessary)				Examiner Name	Jeffery S. Parkin		
Sheet	37	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
2		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823		
		December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823		
	:	August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823		
		June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938		
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938		
		September 7, 2005 Office action in connection with U.S. Application Serial No. 09/888,938		
		August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938		
		May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938		
		June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078		
		December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078		

· · · · · · · · · · · · · · · · · · ·					_
Examiner		· ·	Date		
					10-0
Signature	<i>I</i> /	<u> </u>	Considered	W (~	1 (20)
*EYAMINED: In	ideal if endermore	a pagaidened subother as not citation is in conformance	IN MOTO COO. Deputies thereby	A-Al 4 A 1	

"EXAMINER: Initial if ceterate considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Tredemark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known			
5405414	10 10 10 11 14-07 10			Application Number	09/904,356		
INF	ORMATION	DIS	SCLOSURE	Filing Date	July 12, 2001		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
	Gion de mora etc			Art Unit	1648		
(Use as many sheets as necessary)				Examiner Name	Jeffery S. Parkin		
Sheet	38	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ²
March 23, 1998 Office Action i No. 08/876,078		March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	
Q_{\parallel}		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
+		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	

Examiner Signature	Date Considered	11/12	2/207

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if Teference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if into conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwork Re		ct of 1995, no persons a	a required to respond to a collection of information unless it contains a valid OMB control numb Complete if Known			
Juballa	ile loi loini 1448/FTO			Application Number	09/904,356		
INF	ORMATIO	V DIS	CLOSURE	Filing Date	July 12, 2001		
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
	(Use as many sh	oeta es i	accessed.	Art Unit	1648		
	(Coo as many si	10013 63 1		Examiner Name	Jeffery S. Parkin		
Sheet	39	of	47	Attorney Docket Number	43966-CB		

· ·		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ls
		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	
		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
		May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	

	 			L
Examiner		Date		2007
Signature		Considered	16	100/

^{**}EXAMINER: Initial iPreference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ur	der the Paperwork F	Reduction A	ct of 1995, no persons as	re required to respond to a collection	of Information unless it contains a valid OMB control number. Complete if Known
Substitu	de for form 1449/PT	0		Application Number	09/904,356
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001
STA	STATEMENT BY APPLICANT			First Named Inventor	G.P. Allaway
	(Use as many s	chaota sa i	necessard.	Art Unit	1648
	(050 as many c			Examiner Name	Jeffery S. Parkin
Sheet	40	of	47	Attorney Docket Number	43966-CB

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
\mathcal{A}	(September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
	-	August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
		November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
4		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	

	, · · · · · · · · · · · · · · · · · · ·						
Examiner			Date				
Signature	/ \		Considered	1.	<u> </u>	2	
				111	VCノ	ω	
*EYAMINED. I	itial if callenges second	Sand subadhan an and situation to to condesse.	W MOTO COA D				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with sext communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Ung	der the Paperwork Rec	tuction A	ct of 1995, no persons a	e required to respond to a collection	of information unless it contains a valid C	MB control number.	
Substitute for form 1449/PTO					Complete if Known			
					Application Number	09/904,356		
l	INFO	DRMATION	DIS	CLOSURE	Filing Date	July 12, 2001		
	STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
l		/l les se monu els			Art Unit	1648		
(Use as many sheets as necessary)					Examiner Name	Jeffery S. Parkin		
١	Sheet	41	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7	1	October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	
0		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
		October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
d.		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	

	<u>· </u>			
Examiner	Date	П		
Signature	Considered	111	12/	2007
TEMANNIED A				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007, OMB 0851-0031

Un	der the Paperwork Re	duction A	ct of 1995, no persons ar		and Trademark Office; U.S. DEPARTMENT OF COI of information unless it contains a valid QMB control			
_	te for form 1449/PTO				Complete if Known			
000000	10 101 10111 177017 72			Application Number	09/904,356			
INF	ORMATION	N DIS	CLOSURE	Filing Date	July 12, 2001			
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway			
	***			Art Unit	1648			
(Use as many shoets as necessary)				Examiner Name	Jeffery S. Parkin			
Sheet	42	of	47	Attorney Docket Number	43966-CB			

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
7		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902				
)		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902				
		April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902				
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902				
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902				
		January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902				
		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902				
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902				
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902				
1		August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983				

Examiner		Date		
Signature		Considered	16/17	2 2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007, OMB 0851-0031 rademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons	are required to respond to a collection	of information unless it contains a valid OMB control number.
Substitute for form 1449/PTO		Complete if Known
Substitute for form 1445/2 TO	Application Number	09/904,356
INFORMATION DISCLOSURE	Filing Date	July 12, 2001
STATEMENT BY APPLICANT	First Named Inventor	G.P. Allaway
	Art Unit	1648
(Use as many shoots as necessary)	Examiner Name	Jeffery S. Parkin
Sheet 43 c of 47	Attorney Docket Number	43966-CB

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
~		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	
<u> </u>		July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983	
		December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
		March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983	
		September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983	
		December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545	
		July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
		June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	

			.
Examiner	Date		
Signature	Considered	12	2007

EXAMINER: Initial interprete considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwork Re		ct of 1995, no persons ar	e required to respond to a collection	n of Information unless it contains a valid OMB control number. Complete if Known
Subsulu	14 101 101111 1443/210			Application Number	09/904,356
INF	ORMATION	N DIS	CLOSURE	Filing Date	July 12, 2001
STA	STATEMENT BY APPLICANT			First Named Inventor	G.P. Allaway
	(Use as many sh			Art Unit	1648
	(USE as many so	100 LD 63 1	iecessary)	Examiner Name	Jeffery S. Parkin
Sheet	44	of	47	Attorney Docket Number	43966-CB

	•	NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\mathcal{X}		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
<u> </u>		September 5, 2006 Communication in connection with U.S. Application Serial No. 10/371,483	
		August 21, 2006 Communication in connection with U.S. Application Serial No. 10/371,483	
		May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
		March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
4		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	

		 		<u>ı </u>	<u> </u>
Examiner		Date		ſ	
Signature		Considered	14	12	20))

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance aid not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designar on number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Subattu	de for form 1449/P	TO		Complete if Known			
3008010	AB IOI IOIIII 1773F	.0		Application Number	09/904,356		
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	July 12, 2001		
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
	#100 00 man	b 		Art Unit	1648		
	(Use as many	Sneots as n	eccessary)	Examiner Name	Jeffery S. Parkin		
Sheet	45	of	47	Attorney Docket Number	43966-CB		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\times		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	
<u> </u>		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	·
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	
		May 24, 2006 Supplementary European search report under Article 157(2)(a) EPC in connection with European Application No. 01970984.9	
Je		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	

Examiner /	Date	
Signature	Considered 11/12/2000	

EXAMINER: Initial if reference considered, whether pract citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Substitute for form 1449/PTO	on Act of 1995, no persons ar	re required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitute for form 1443/P10		Application Number	09/904,356
INFORMATION D	DISCLOSURE	Filing Date	July 12, 2001
STATEMENT BY	APPLICANT	First Named Inventor	G.P. Allaway
///aa aa magaa ahaata		Art Unit	1648
(Use as many sheets	as necessary)	Examiner Name	Jeffery S. Parkin
Sheet 46	of 47	Attorney Docket Number	43966-CB

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9			
1		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615	
		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
	·	February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615	
		February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	
V		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797	

					<u> </u>
Examiner		Date	•	(2
Signature	/	Considered	10	12	14007

EXAMINER: Initial if presence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique distion designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Subattur	te for form 1449/PTC			Complete if Known			
3008414	io ioi ibiiii 144air 10	•		Application Number	09/904,356		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 12, 2001	_	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
		.		Art Unit	1648	_	
	(Use as many s	neets as n	iecessary)	Examiner Name	Jeffery S. Parkin		
Sheet	47	of	47	Attorney Docket Number	43966-CB	Ī	

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
A		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797			
1		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,			
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938			
		Bieniasz, P.D., et al. (1997). HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor. EMBO, 16:2599-2609			
		Blanpain, C., et al. (1999). Multiple Charged And Aromatic Residues In CCR5 In High Affinity Binding Of Both Chemokines And HIV-1 J. Biol. Chem., 274:34719-34727			
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311			
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311			
		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311			
•		August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311			

Examiner		_	Date		. 7	_
Signature	(Considered	10/1	12/1	(CO)

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this-form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.